Analyst RatingAnalyst maintains a BUY rating and raises the 12-month price target to $2.75, suggesting significant upside from the current share price.
Growth PotentialThe company's intention to acquire Neuro-Kinesis Corporation, which is advancing medical technology, presents a potential growth opportunity.
Market OpportunityThe potential billion-dollar market for PURE EP presents high rewards for the risks, making an investment in BioSig compelling.
Product DevelopmentThe company has developed the PURE EP system, an FDA-cleared device providing essential diagnostic signals during cardiac catheter ablations.